Further evidence highlights the potential of molecularly guided combinations, such as sitravatinib, a TAM kinase inhibitor that enhances PD-1 inhibitor efficacy through tumor microenvironment remodeling, achieving a 31.6% disease control rate (DCR) in gastroesophageal junction cancer (97). This evidence concerns the gene PDCD1 and neoplasm.